TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

10 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Kidney disease

    Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis

    Testing amino acid supplements during hemodialysis for fatigue and thinking in end-stage kidney

    📍 The University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    The study will test and compare the efficacy of a single essential amino acid valine with a combination of essential amino acids (EAA) supplement on fatigue, frailty, and cognitive function in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD) treatment.

    ✓ Study care freeEarly Phase 1Ages 18–64Learn more →
  • Multiple sclerosis (MS)

    Entire-body PET Scans for Multiple Sclerosis

    Testing whether whole-body PET scans can better track MS brain and nerve damage

    📍 Brain Health Alliance · Ladera Ranch, CA · Get directions →

    To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.

    ✓ Study care freeEarly Phase 1Ages 25–55Learn more →
  • Kidney disease

    Concomitant Renal and Urinary Bladder Allograft Transplantation

    Testing whether transplanting a new kidney and bladder at the same time is possible for people with

    📍 Mayo Clinic · Rochester, MN · +1 more US site · Get directions →

    The purpose of this study is to establish if concomitant renal and vascularized urinary bladder allograft transplantation is feasible.

    ✓ Study care freeEarly Phase 1Ages 1–60Learn more →
  • Kidney disease

    Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease

    Testing whether a trial of SGLT2 inhibitors in youth with chronic kidney disease is feasible

    📍 Ann & Robert H. Lurie Children's Hospital of Chicago · Chicago, IL · Get directions →

    The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease.

    ✓ Study care freeEarly Phase 1Ages 12–25Learn more →
  • Migraine / chronic headache

    Mechanistic Studies of Psilocybin in Headache Disorders

    Testing how psilocybin may affect migraine headache symptoms

    📍 VA Connecticut Healthcare System · West Haven, CT · Get directions →

    In previous clinical trial work, the investigators observed lasting reductions in headache burden after limited dosing of psilocybin. This purpose of this study is to examine potential sources for this observed effect.

    ✓ Study care freeEarly Phase 1Ages 21–70Learn more →
  • Type 2 diabetesKidney disease

    Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease

    Testing whether people with type 2 diabetes have early hormone-related kidney risk

    📍 Brigham and Women's Hospital · Boston, MA · Get directions →

    The aim of this protocol is to assess the presence and severity of primary aldosteronism pathophysiology in patients with type 2 diabetes who have, or are at-risk for developing, chronic kidney disease.

    ✓ Study care freeEarly Phase 1Ages 18–80Learn more →
  • Lupus (SLE)

    Safety and Efficacy of ONT01 in Lupus

    Studying whether ONT01 is safe and tolerated in people with lupus

    📍 Hospital for Special Surgery · New York, NY · Get directions →

    ONT01 is a drug that is being studied for the treatment of Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) and is not approved by the FDA. The purpose of this study is to better determine whether ONT01 is safe and tolerated by people with lupus nephritis or SLE.

    ✓ Study care freeEarly Phase 1Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Effects of Ublituximab on Motor Functions in Multiple Sclerosis

    Testing whether ublituximab changes walking and fall risk in people with relapsing multiple

    📍 Georgia State University · Atlanta, GA · +1 more US site · Get directions →

    The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment.

    ✓ Study care freeEarly Phase 1Ages 18–55Learn more →
  • Migraine / chronic headache

    Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs?

    Testing whether a nerve block plus steroid tablets lowers migraine headache return within 72 hours

    📍 University Medical Center of El Paso · El Paso, TX · Get directions →

    For some patients who come to the emergency department for treatment of a migraine headache, peripheral headache nerve blocks (PHNB) have proven to be an efficient and effective treatment for headache relief. Previous studies have demonstrated that adding steroids as an adjunct treatment to standard migraine treatment can reduce recurrence of headaches in the subsequent few days.

    ✓ Study care freeEarly Phase 1Ages 18–85Learn more →
  • Multiple sclerosis (MS)

    Assessment of Synaptic Density in MS

    Testing brain imaging to measure synapse density in progressive MS

    📍 Brigham and Women's Hospital · Boston, MA · Get directions →

    The investigators propose to use the novel SV2a-PET ligand, \[F-18\]SDM-8 to assess synaptic density in progressive multiple sclerosis (PMS) (including primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS)), given its improved imaging characteristics and potential for large scale applicability. The specific aims of the study are: Aim 1: To compare the cortical and subcortical grey matter synaptic density in PMS patients, patients with relapsing-remitting MS (RRMS), and healthy subjects, using a novel \[F-18\] labeled synaptic density PET ligand, \[F-18\]SDM8, also known as \[F-18\]SynvesT-1.

    ✓ Study care freeEarly Phase 1Ages 18–60Learn more →